AOD-9604 10mg
AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH), commonly described as the hGH 176–191 fragment with an additional N-terminal tyrosine. It is studied primarily in lipid metabolism, adipocyte biology, lipolysis, lipogenesis, peptide pharmacology, and metabolic signaling, with research examining its interaction with pathways involved in fat metabolism and its separation from the classical growth-hormone receptor signaling pathway..
Compound information
What is the Peptide?
A laboratory-made piece of human growth hormone, taken from its fat-metabolizing tail region and given an extra tyrosine for stability. It reproduces that region's lipolytic behavior in research models while leaving the receptor and blood-sugar effects of full growth hormone behind.
Structure
Stability information
Product overview
A lipolytic growth-hormone fragment supplied for laboratory evaluation at a ≥99% HPLC analytical standard.
Technical overview
AOD-9604 corresponds to the 176-to-191 segment at the tail of human growth hormone, the portion linked to fat metabolism, with a tyrosine added at the front end and a disulfide bridge joining its two cysteine residues. That tyrosine lends it stability without engaging the growth-hormone receptor.
It is produced by solid-phase synthesis and preparative purification, then released against a lot-matched Certificate of Analysis carrying HPLC purity and LC-MS identity.
Research applications
Researchers use AOD-9604 as a fragment tool for isolating the lipolytic activity of growth hormone from its wider signaling. Typical work includes glycerol-release lipolysis assays in adipocytes, adipocyte-differentiation and lipogenesis models, side-by-side comparisons of the fragment against intact growth hormone, and structure-activity studies of the hGH lipolytic domain.
Kylo Peptides supplies this compound as a reference material for scientific inquiry. All applications must be conducted by qualified professionals in controlled laboratory environments. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Researched Together
Frequently Asked Questions
It carries only the fat-metabolizing portion. AOD-9604 reproduces the lipolytic behavior of the C-terminal region of growth hormone without binding the GH receptor, so in research models it does not raise IGF-1 or affect blood sugar the way intact growth hormone does. That separation is precisely what makes it useful as a tool compound.
They cover the same region of growth hormone but are not identical. AOD-9604 adds a tyrosine at the N-terminus that the plain 176-191 fragment lacks, a change originally made to aid tracing and later kept for the modest stability it provides. The two are often confused but remain distinct molecules.
Analysis puts every lot at ≥99% by HPLC, with LC-MS confirming identity. Independent third-party testing clears each batch before release, and you can pull the certificate for your lot using the number on the vial.
Frozen and dry is the rule: −20 °C for routine holding, −80 °C when storing longer, always sealed and shielded from light. After you reconstitute it, move the solution to 2 to 8 °C, work through it within a validated window, and do not cycle it repeatedly through freezing and thawing.
Yes, as a drug candidate. An Australian company conducted Phase I and Phase II obesity trials between 2001 and 2007, in which its safety profile matched placebo, but its weight-loss effect did not reach statistical significance in the larger study, and development was halted. It exists today only as a research compound.
No. What Kylo supplies is research-grade material for in vitro laboratory work alone. It is not prepared or labeled for people or animals and is not a stand-in for any approved or investigational drug. It is sold only as a characterized reagent for qualified researchers.
Backed By A Lot-Matched COA
Every AOD-9604 order is tied to a certificate of analysis matched to the exact lot in your vial.
Shop catalog →
